Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2016 1
2018 1
2019 2
2020 4
2021 3
2022 5
2023 10
2024 11
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Transrectal versus transperineal prostate fusion biopsy: a pair-matched analysis to evaluate accuracy and complications.
Oderda M, Diamand R, Abou Zahr R, Anract J, Assenmacher G, Barry Delongchamps N, Bui AP, Benamran D, Calleris G, Dariane C, Ferriero M, Fiard G, Taha F, Fourcade A, Fournier G, Guenzel K, Halinski A, Marra G, Ploussard G, Rysankova K, Roche JB, Simone G, Windisch O, Gontero P. Oderda M, et al. Among authors: roche jb. World J Urol. 2024 Sep 25;42(1):535. doi: 10.1007/s00345-024-05245-1. World J Urol. 2024. PMID: 39320521 Free PMC article.
Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracy.
Diamand R, Peltier A, Roche JB, Lievore E, Lacetera V, Chiacchio G, Beatrici V, Mastroianni R, Simone G, Windisch O, Benamran D, Fourcade A, Nguyen TA, Fournier G, Fiard G, Ploussard G, Roumeguère T, Albisinni S. Diamand R, et al. Among authors: roche jb. World J Urol. 2023 Jan;41(1):77-84. doi: 10.1007/s00345-022-04244-4. Epub 2022 Dec 12. World J Urol. 2023. PMID: 36509932
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.
Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R. Mjaess G, et al. Among authors: roche jb. Prostate Cancer Prostatic Dis. 2025 Mar;28(1):173-179. doi: 10.1038/s41391-024-00872-6. Epub 2024 Jul 24. Prostate Cancer Prostatic Dis. 2025. PMID: 39048664
BACKGROUND: Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified through multiparametric magnetic resonance imaging (mpMRI), present a clinical challenge due to their equivocal nature in predicting clinically significant prostate cancer (csPCa). Aim o …
BACKGROUND: Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified through multiparametric magnetic resonance imaging (m …
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach.
Baboudjian M, Breda A, Roumeguère T, Uleri A, Roche JB, Touzani A, Lacetera V, Beauval JB, Diamand R, Simone G, Windisch O, Benamran D, Fourcade A, Fiard G, Durand-Labrunie C, Roumiguié M, Sanguedolce F, Oderda M, Barret E, Fromont G, Dariane C, Charvet AL, Gondran-Tellier B, Bastide C, Lechevallier E, Palou J, Ruffion A, Van Der Bergh RCN, Peltier A, Ploussard G. Baboudjian M, et al. Among authors: roche jb. World J Urol. 2023 May;41(5):1301-1308. doi: 10.1007/s00345-023-04353-8. Epub 2023 Mar 15. World J Urol. 2023. PMID: 36920491
PURPOSE: To develop new selection criteria for active surveillance (AS) in intermediate-risk (IR) prostate cancer (PCa) patients. METHODS: Retrospective study including patients from 14 referral centers who underwent pre-biopsy mpMRI, image-guided biopsies and radical pros …
PURPOSE: To develop new selection criteria for active surveillance (AS) in intermediate-risk (IR) prostate cancer (PCa) patients. MET …
Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
Fitoussi O, Roche JB, Riviere J, Wallerand H, Poulain JE, Gordien P, Galland S, Henriques B, Dupin C, Vincent M, Kuratle T, Saffarini M, Ramos-Pascual S. Fitoussi O, et al. Among authors: roche jb. Urol Int. 2023;107(3):239-245. doi: 10.1159/000528524. Epub 2023 Jan 19. Urol Int. 2023. PMID: 36657430
INTRODUCTION: The aim of the study was to confirm the diagnostic accuracy of a second FDG-PET/CT following neoadjuvant or induction chemotherapy (NAIC) prior to radical cystectomy for patients with localized muscle-invasive bladder cancer (MIBC). METHODS: Retrospective rev …
INTRODUCTION: The aim of the study was to confirm the diagnostic accuracy of a second FDG-PET/CT following neoadjuvant or induction chemothe …
Outcomes of lateral approach in robot-assisted radical prostatectomy: insights from a single-surgeon experience.
Giulioni C, Castellani D, Vuong NS, Riviere J, Piechaud-Kressmann J, Lopez LH, Piechaud T, Roche JB, Rouffilange J, Hoepffner JL, Galosi AB, Gaston RP, Pierquet G. Giulioni C, et al. Among authors: roche jb. J Robot Surg. 2024 Jan 13;18(1):24. doi: 10.1007/s11701-023-01772-y. J Robot Surg. 2024. PMID: 38217830 Free PMC article.
We conducted a retrospective analysis of 70 prostate cancer patients who underwent LRRP between October 2019 and September 2021, analyzing the perioperative and functional outcomes. ...Our analysis shows that LRRP is a safe and effective procedure for prostate cancer …
We conducted a retrospective analysis of 70 prostate cancer patients who underwent LRRP between October 2019 and September 2021, anal …
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
Diamand R, Peltier A, Roche JB, Lievore E, Lacetera V, Chiacchio G, Beatrici V, Mastroianni R, Simone G, Windisch O, Benamran D, Fourcade A, Nguyen TA, Fournier G, Fiard G, Ploussard G, Roumeguère T, Albisinni S. Diamand R, et al. Among authors: roche jb. Prostate. 2023 May;83(6):572-579. doi: 10.1002/pros.24490. Epub 2023 Jan 27. Prostate. 2023. PMID: 36705314
BACKGROUND: Multiparametric magnetic resonance imaging (MRI) and MRI-targeted biopsy are nowadays recommended in the prostate cancer (PCa) diagnostic pathway. Ploussard and Mazzone have integrated these tools into novel risk classification systems predicting the risk of ea …
BACKGROUND: Multiparametric magnetic resonance imaging (MRI) and MRI-targeted biopsy are nowadays recommended in the prostate cancer …
Predicting contralateral extraprostatic extension in unilateral high-risk prostate cancer: a multicentric external validation study.
Diamand R, Roche JB, Lacetera V, Simone G, Windisch O, Benamran D, Fourcade A, Fournier G, Fiard G, Ploussard G, Roumeguère T, Peltier A, Albisinni S. Diamand R, et al. Among authors: roche jb. World J Urol. 2024 Apr 22;42(1):247. doi: 10.1007/s00345-024-04966-7. World J Urol. 2024. PMID: 38647728
Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The aim of the study is to externally validate this model in a multicentric European cohort of patients. ...
Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The …
Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection.
Diamand R, Guenzel K, Mjaess G, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Benijts J, Assenmacher G, Roumeguère T, Peltier A. Diamand R, et al. Among authors: roche jb. Eur Urol Focus. 2024 Sep;10(5):805-811. doi: 10.1016/j.euf.2024.03.003. Epub 2024 Mar 19. Eur Urol Focus. 2024. PMID: 38508895
The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to compare the csPCa detection rate of TRBx and TPBx. ...Our results suggest that the perineal approach is associated with better detection of …
The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to …
External Validation of Models for Prediction of Side-specific Extracapsular Extension in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Diamand R, Roche JB, Lievore E, Lacetera V, Chiacchio G, Beatrici V, Mastroianni R, Simone G, Windisch O, Benamran D, Favre MM, Fourcade A, Nguyen TA, Fournier G, Fiard G, Ploussard G, Roumeguère T, Peltier A, Albisinni S. Diamand R, et al. Among authors: roche jb. Eur Urol Focus. 2023 Mar;9(2):309-316. doi: 10.1016/j.euf.2022.09.006. Epub 2022 Sep 21. Eur Urol Focus. 2023. PMID: 36153227
BACKGROUND: Predicting the risk of side-specific extracapsular extension (ECE) is essential for planning nerve-sparing radical prostatectomy (RP) in patients with prostate cancer (PCa). OBJECTIVE: To externally validate available models for prediction of ECE. ...They could …
BACKGROUND: Predicting the risk of side-specific extracapsular extension (ECE) is essential for planning nerve-sparing radical prostatectomy …
32 results